MET Amplification and Efficacy of Nivolumab in Patients With NSCLC

Introduction: MET amplification is an important genetic alteration in NSCLC. Unlike in patients with EGFR and ALK alterations, the efficacy of immune checkpoint inhibitors in patients with MET-amplified NSCLC remains unknown. Methods: An exploratory analysis of a prospective, multi-institutional coh...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Katsuhiro Yoshimura, MD, PhD, Yusuke Inoue, MD, PhD, Naoki Inui, MD, PhD, Masato Karayama, MD, PhD, Hideki Yasui, MD, PhD, Hironao Hozumi, MD, PhD, Yuzo Suzuki, MD, PhD, Kazuki Furuhashi, MD, PhD, Tomoyuki Fujisawa, MD, PhD, Noriyuki Enomoto, MD, PhD, Yutaro Nakamura, MD, PhD, Haruhiko Sugimura, MD, PhD, Takafumi Suda, MD, PhD
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Elsevier 2021-11-01
Serie:	JTO Clinical and Research Reports
Ämnen:	Lung cancer MET Nivolumab Amplification Immune checkpoint inhibitor
Länkar:	http://www.sciencedirect.com/science/article/pii/S2666364321000989
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!